Expressing the Promise of
Your Protein
Our Mission Statement
Be a world-class CMO that excels as a strategic partner to deliver the highest quality material from proof of concept through Phase I / II clinical trials by employing superior cGMP compliant services that enable cost-effective, on-time delivery of our client's pre-clinical and clinical supplies to enhance patient's lives.
Define Your Need With A Strategic Partner
GBI is dedicated to partnering with you on your project, whether it is a novel protein or a Biosimilar / Biobetter.
GBI is dedicated to partnering with you on your project. We can be a one-stop shop or we can help determine where we can add the most value when you need us anywhere along the process:
- Cell lines developed from cDNA
- Proof of Concept
- Assay Tech Transfer
- Assay Verification
- Research Cell Bank
- Master / Working Cell Bank
- Cell Culture Process Development
- Protein Purification
- Engineering / Pilot Run
- cGMP Manufacturing for Phase I/II Clinical Trials
Upcoming Events And Appearances
To schedule an appointment with a GBI representative at any of the
following events, please contact:
Dave Cunningham
Director of Marketing
Phone: (954) 327-9639
Email: DCunningham@goodwinbio.com
Join us at:
|
Washington Marriott Hotel, Washington, DC
The World RadioImmunoConjugate Summit is the only industry focused forum on radioimmunotherapy and radiolabeled imaging. Exciting new developments in alpha particle therapy and immunoPET imaging have led to a new generation of cancer fighting drugs just waiting to explode onto the market. There has never been a more exciting time to be working with radioimmunoconjugates, and never been a better opportunity to learn from, and network with, your peers across this exciting field.
|
|
At BIO International, you can learn about the key global developments that will shape the biotech industry, and what companies will need to do in order to remain competitive in a world being influenced by a tougher financial climate, rapidly evolving technology, globalization and new emerging markets. In addition, visit us at Booth number 1200 to explore the right partnership for your organization.
|
|
The Stanford Court Renaissance Hotel,San Francisco, CA
The World ADC Summit returns. The leading experts in antibody-drug conjugate development are already putting their minds together to plan and prepare for this stellar event. Building on a platform of well-received events in Boston and Frankfurt, we are designing the most exciting, most interesting and most up-to-date insight into the ADC landscape.
|
|
Click here to download brochure
The Art of Bioconjugation
Conjugation of monoclonal antibodies and recombinant proteins with other molecules is a specialty of GBI's development and manufacturing groups. Whether the conjugate is a drug toxin (small molecule cancer drugs, plant protein toxins), chelating agents for radio isotopes labeling (diagnostics and therapeutics), adjuvants such as Aluminum Hydroxide-Antibody conjugate, or other antibodies, GBI has the ability to develop and perform them at GMP compliant manufacturing scales for clinical applications. For more information on our Bioconjugation experience, click here.
Biosimilars / Biobetters
An Opportunity
Biologicals represent the fastest growing segment of the pharmaceutical market and over 30 branded biologics with sales in excess of $50 billion are facing patent expirations. That yields a significant business opportunity to develop Biosimilars and Biobetters.
Read more
* The radioisotope image is provided as a courtesy from Ekaterina (Kate) Dadachova, PhD and Arturo Casadevall, MD, PhD as published in Einstein’s dynamic duo of the decade.
Einstein. 2010; Summer / Fall:38-45.
|
